➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Moodys
Mallinckrodt
Johnson and Johnson
Colorcon

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,783,412

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,783,412
Title: Hybrid DNA synthesis of epidermal growth factor
Abstract:DNA sequences and methods of obtaining DNA sequences which include a sequence encoding for mammalian epidermal growth factor are provided. The DNA sequences may be used in cloning and expression vectors for production of DNA and RNA and for producing polypeptides including mammalian epidermal growth factor. E. coli strains HB 101 (pmegf1) and HB 101 (pmegf10b), and bacteriophage .lambda.hEGF34 were deposited at the A.T.C.C. on May 10, 1983 and given Accession Nos. 39357, 39358 and 40070, respectively.
Inventor(s): Bell; Graeme I. (San Francisco, CA)
Assignee: Chiron Corporation (Emeryville, CA)
Application Number:07/058,706
Patent Claims:1. A composition comprising DNA molecules containing a nucleotide sequence encoding human epidermal growth factor (EGF) and substantially free of DNA molecules that do not contain said nucleotide sequence, said EGF-encoding nucleotide sequence comprising: ##STR2##

2. The composition of claim 1 whrein said DNA molecules are episomal elements.

3. A composition comprising cells containing an intron free DNA sequence encoding human epidermal growth factor (EGF) substantially free of cells not containing said EGF-encoding DNA sequence, said EGF-encoding DNA sequence comprising: ##STR3##

4. The composition of claim 3 wherein said cells are bacteria.

5. The composition of claim 3 wherein said cells are yeast.

Details for Patent 4,783,412

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial Chiron Corporation (Emeryville, CA) 2006-01-24 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial Chiron Corporation (Emeryville, CA) 2006-01-24 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial Chiron Corporation (Emeryville, CA) 2006-01-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Mallinckrodt
Baxter
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.